[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Tyra Biosciences Inc (TYRA)

Tyra Biosciences Inc (TYRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,986,298
  • Shares Outstanding, K 59,470
  • Annual Sales, $ 0 K
  • Annual Income, $ -119,950 K
  • EBIT $ -143 M
  • EBITDA $ -142 M
  • 60-Month Beta 0.79
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.18

Options Overview Details

View History
  • Implied Volatility 81.19% (+1.24%)
  • Historical Volatility 46.36%
  • IV Percentile 6%
  • IV Rank 10.50%
  • IV High 357.21% on 09/12/25
  • IV Low 48.81% on 09/09/25
  • Expected Move (DTE 28) 4.65 (13.96%)
  • Put/Call Vol Ratio 1.04
  • Today's Volume 108
  • Volume Avg (30-Day) 36
  • Put/Call OI Ratio 1.04
  • Today's Open Interest 1,311
  • Open Int (30-Day) 1,611
  • Expected Range 28.66 to 37.96

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.68
  • Number of Estimates 6
  • High Estimate $-0.65
  • Low Estimate $-0.70
  • Prior Year $-0.47
  • Growth Rate Est. (year over year) -44.68%

Price Performance

See More
Period Period Low Period High Performance
1-Month
32.26 +2.88%
on 05/07/26
38.63 -14.08%
on 04/27/26
-3.50 (-9.54%)
since 04/21/26
3-Month
30.10 +10.27%
on 03/03/26
40.65 -18.35%
on 04/01/26
+1.61 (+5.10%)
since 02/20/26
52-Week
8.75 +279.31%
on 05/28/25
40.65 -18.35%
on 04/01/26
+23.43 (+240.06%)
since 05/21/25

Most Recent Stories

More News
TYRA BIOSCIENCES AND BCAN ESTABLISH MAY 21 AS UPPER TRACT UROTHELIAL CANCER (UTUC) AWARENESS DAY

-Collaboration aims to raise awareness of UTUC and the need for continued innovation for patients living with this rare and difficult-to-treat cancer-

TYRA : 33.17 (-0.69%)
Tyra Biosciences Earnings May Expose Whether Wall Street Confused Pipeline Activity With Progress

Barchart Research What to Expect from TYRA Earnings TYRA Generated May 13, 2026 Current Price $36.18 EPS Estimate $$-0.60 Consensus Rating Strong Buy Average Move 3.14% Tyra Biosciences Earnings May Expose...

TYRA : 33.17 (-0.69%)
Tyra Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights

- Advanced " dabogratinib 3x3 "  strategy to pursue 3 late-stage clinical studies in LG-UTUC, IR NMIBC and ACH -

TYRA : 33.17 (-0.69%)
Tyra Biosciences to Participate in Upcoming Investor Conferences

CARLSBAD, Calif. , May 7, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target...

TYRA : 33.17 (-0.69%)
Tyra Biosciences Announces Appointment of Habib Dable to its Board of Directors

- Seasoned biopharmaceutical leader brings deep commercial and strategic expertise to support TYRA's next phase of growth-

TYRA : 33.17 (-0.69%)
Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights

- Launched " dabogratinib 3x3 "  strategy to pursue 3 late-stage clinical studies in LG-UTUC, IR NMIBC and ACH, 3 potential blockbuster indications -

TYRA : 33.17 (-0.69%)
Tyra Biosciences Announces Poster Presentations at the 2026 ASCO® Genitourinary (GU) Cancers Symposium

CARLSBAD, Calif. , Feb. 23, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target...

TYRA : 33.17 (-0.69%)
Tyra Biosciences to Participate in Upcoming Investor Conferences

CARLSBAD, Calif. , Feb. 19, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target...

TYRA : 33.17 (-0.69%)
Tyra Biosciences Strengthens Leadership Team with Appointments of Bhavesh Ashar as Chief Operating Officer and Heather Faulds as Chief Regulatory Officer

CARLSBAD, Calif. , Dec. 1, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target...

TYRA : 33.17 (-0.69%)
3 Biotech Stocks Wall Street Analysts Predict Will More Than Double

What makes analysts so bullish about these three names from the sector?

MEHCQ : 3.5000 (-2.78%)
GHRS : 21.83 (-3.15%)
TYRA : 33.17 (-0.69%)
DMAC : 5.79 (+1.22%)
XBI : 132.72 (+0.77%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Tyra Biosciences Inc. is a precision oncology company. It focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. The company's lead product candidate includes TYRA-300. Tyra Biosciences Inc. is based in CARLSBAD, Calif.

See More

Key Turning Points

3rd Resistance Point 35.81
2nd Resistance Point 35.31
1st Resistance Point 34.36
Last Price 33.17
1st Support Level 32.91
2nd Support Level 32.41
3rd Support Level 31.46

See More

52-Week High 40.65
Last Price 33.17
Fibonacci 61.8% 28.46
Fibonacci 50% 24.70
Fibonacci 38.2% 20.94
52-Week Low 8.75

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.